Added to YB: 2026-10-09
Pitch date: 2026-10-04
XFOR [bullish]
X4 Pharmaceuticals, Inc.
-8.33%
current return
Author Info
No bio for this author
Company Info
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
Market Cap
$274.6M
Pitch Price
$2.88
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.85
P/E
-3.12
EV/Sales
9.08
Sector
Biotechnology
Category
special_situation
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - X4 Pharmaceuticals, Inc.
XFOR (hold): X4 Pharmaceuticals is a rare-disease commercial story centered on mavorixafor for WHIM syndrome, with a defined label, specialist patient base and potential buyers experienced in rare immunology and hematology. However, the indication is too small by itself to create consolidation urgency; launch performance, diagnosis rates, payer access and lifecycle expansion will determine whether the franchise moves beyond satellite status.
Read full article (1 min)